(RTTNews) - Axsome Therapeutics, Inc. (AXSM) Monday said the Phase 3 SYMPHONY study of its drug candidate AXS-12 for the treatment of narcolepsy met its primary goal. Narcolepsy is a brain and nervous ...

Phase 3 persevERA missed the primary endpoint, with no statistically significant improvement in investigator-assessed PFS for giredestrant plus palbociclib versus letrozole plus palbociclib in the ITT ...

Roche said its fenebrutinib drug candidate met primary goals in two late-stage trials for multiple sclerosis, reducing attacks or delaying disability progression in two different forms of the disease.

(RTTNews) - Merck & Co Inc. (MRK) Monday announced positive topline results from the Phase 3 HYPERION study evaluating Winrevair in adults with recently diagnosed pulmonary arterial hypertension (PAH) ...

FRANKFURT (Reuters) -Swiss drugmaker Roche said on Monday that a late-stage trial testing ‌its multiple sclerosis drug candidate fenebrutinib against the relapsing form ‌of the disease achieved its ...